Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse
Esther Onecha(Hospital Universitario 12 De Octubre), Rosa Ayala(Hospital Universitario 12 De Octubre), María Linares(Universidad Complutense de Madrid), Inmaculada Rapado(Wellcome Sanger Institute), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Xabier Gutiérrez(Hospital Universitario 12 De Octubre), Gonzalo Carreño‐Tarragona, Miguel Gallardo(Spanish National Cancer Research Centre), Pilar Martínez‐Sánchez(Hospital Universitario 12 De Octubre), José María Sáchez Pina(Hospital Universitario 12 De Octubre), María Luz Morales(Research Institute Hospital 12 de Octubre)
Cited by 35
Related Papers
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523